Heart Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Heart Disease
Researchers' work from National Heart, Lung, & Blood Institute focuses on heart disease
December 28th, 2008
"Clinical trials of postmenopausal hormone therapy (HT) have shown increased risk of coronary heart disease (CHD) in the first few years after initiation of therapy and no overall benefit. This nested case-control study evaluates a range of inflammatory, lipid, thrombotic, and genetic markers for their association with CHD in the 4 years after randomization and assesses whether any of these markers modified or mediated the initially increased risk associated with HT in postmenopausal women aged 50 to 79 years at baseline," scientists in the United States report. "Conjugated equine estrogens, 0.625 mg/d, or placebo was given to 10 739 hysterectomized women, and the same...
Source: Heart Disease Weekly (2008-12-28)
|
